Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease.

Markey KA, MacDonald KP, and Hill GR. 2014. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 124: 354–362.

Zeiser R, and Blazar BR. 2017. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. The New England journal of medicine 377: 2167–2179.

Sakaguchi S 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455–458.

Taylor PA, Lees CJ, and Blazar BR. 2002. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493–3499.

Hoffmann P, Ermann J, Edinger M, Fathman CG, and Strober S. 2002. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. The Journal of experimental medicine 196: 389–399.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, and Negrin RS. 2003. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature medicine 9: 1144–1150.

Beres AJ, and Drobyski WR. 2013. The role of regulatory T cells in the biology of graft versus host disease. Frontiers in immunology 4: 163.

Blazar BR, MacDonald KPA, and Hill GR. 2018. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy. Blood.

Beres A, Komorowski R, Mihara M, and Drobyski WR. 2011. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clinical cancer research : an official journal of the American Association for Cancer Research 17: 3969–3983.

Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, and Drobyski WR. 2012. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. Journal of immunology (Baltimore, Md. : 1950) 189: 464–474.

Heinrichs J, Li J, Nguyen H, Wu Y, Bastian D, Daethanasanmak A, Sofi MH, Schutt S, Liu C, Jin J, Betts B, Anasetti C, and Yu XZ. 2016. CD8(+) Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4(+) Tregs in mice. Oncoimmunology 5: e1146842.

Zheng J, Liu Y, Liu Y, Liu M, Xiang Z, Lam KT, Lewis DB, Lau YL, and Tu W. 2013. Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Science translational medicine 5: 168–169.

Lerret NM, Houlihan JL, Kheradmand T, Pothoven KL, Zhang ZJ, and Luo X. 2012. Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 12: 2335–2347.

Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, Varelias A, Alexander KA, Teal BE, Sparwasser T, Hammerling GJ, Markey KA, Koyama M, Clouston AD, Engwerda CR, Hill GR, and MacDonald KP. 2012. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood 119: 5898–5908.

Sawamukai N, Satake A, Schmidt AM, Lamborn IT, Ojha P, Tanaka Y, and Kambayashi T. 2012. Cell-autonomous role of TGFbeta and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. Blood 119: 5575–5583.

Suzuki M, Jagger AL, Konya C, Shimojima Y, Pryshchep S, Goronzy JJ, and Weyand CM. 2012. CD8+CD45RA+CCR7+FOXP3+ T cells with immunosuppressive properties: a novel subset of inducible human regulatory T cells. Journal of immunology (Baltimore, Md. : 1950) 189: 2118–2130.

Zhong H, Liu Y, Xu Z, Liang P, Yang H, Zhang X, Zhao J, Chen J, Fu S, Tang Y, Lv J, Wang J, Olsen N, Xu A, and Zheng SG. 2018. TGF-beta-Induced CD8(+)CD103(+) Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells. Frontiers in immunology 9: 35.

Agle K, Vincent BG, Piper C, Belle L, Zhou V, Shlomchik W, Serody JS, and Drobyski WR. 2018. Bim regulates the survival and suppressive capability of CD8(+) FOXP3(+) regulatory T cells during murine GVHD. Blood.

Laurence A, Amarnath S, Mariotti J, Kim YC, Foley J, Eckhaus M, O’Shea JJ, and Fowler DH. 2012. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity 37: 209–222.

Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O’Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, and Yu XZ. 2018. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America 115: 1582–1587.

Betts BC, Abdel-Wahab O, Curran SA, St Angelo ET, Koppikar P, Heller G, Levine RL, and Young JW. 2011. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood 118: 5330–5339.

Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, and Pidala J. 2015. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. Journal of leukocyte biology 97: 807–819.

Betts BC, Veerapathran A, Pidala J, Yu XZ, and Anasetti C. 2014. STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity. Journal of leukocyte biology 95: 205–213.

Radojcic V, Pletneva MA, Yen HR, Ivcevic S, Panoskaltsis-Mortari A, Gilliam AC, Drake CG, Blazar BR, and Luznik L. 2010. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. Journal of immunology (Baltimore, Md. : 1950) 184: 764–774.

Tawara I, Sun Y, Liu C, Toubai T, Nieves E, Evers R, Alrubaie M, Mathewson N, Tamaki H, and Reddy P. 2012. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. Journal of leukocyte biology 91: 667–675.

Chen Q, Kim YC, Laurence A, Punkosdy GA, and Shevach EM. 2011. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. Journal of immunology (Baltimore, Md. : 1950) 186: 6329–6337.

Thornton AM, Donovan EE, Piccirillo CA, and Shevach EM. 2004. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. Journal of immunology (Baltimore, Md. : 1950) 172: 6519–6523.

Frank DA, Robertson MJ, Bonni A, Ritz J, and Greenberg ME. 1995. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proceedings of the National Academy of Sciences of the United States of America 92: 7779–7783.

Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, and Bromberg JS. 2009. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. Journal of immunology (Baltimore, Md. : 1950) 182: 259–273.

Sasidharan Nair V, Song MH, and Oh KI. 2016. Vitamin C Facilitates Demethylation of the Foxp3 Enhancer in a Tet-Dependent Manner. Journal of immunology (Baltimore, Md. : 1950) 196: 2119–2131.

Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, Perez-Melgosa M, Sweetser MT, Schlissel MS, Nguyen S, Cherry SR, Tsai JH, Tucker SM, Weaver WM, Kelso A, Jaenisch R, and Wilson CB. 2001. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15: 763–774.

Sharma S, and Zhu J. 2014. Immunologic applications of conditional gene modification technology in the mouse. Curr Protoc Immunol 105: 10 34 11–13.

Nguyen HD, Chatterjee S, Haarberg KM, Wu Y, Bastian D, Heinrichs J, Fu J, Daenthanasanmak A, Schutt S, Shrestha S, Liu C, Wang H, Chi H, Mehrotra S, and Yu XZ. 2016. Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation. The Journal of clinical investigation 126: 1337–1352.

Somervaille TC, and Cleary ML. 2006. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10: 257–268.

Zhang J, Ramadan AM, Griesenauer B, Li W, Turner MJ, Liu C, Kapur R, Hanenberg H, Blazar BR, Tawara I, and Paczesny S. 2015. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Science translational medicine 7: 308–160.

Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst CN, Xiong H, Dolpady J, Frey AB, Ruocco MG, Yang Y, Floess S, Huehn J, Oh S, Li MO, Niec RE, Rudensky AY, Dustin ML, Littman DR, and Lafaille JJ. 2012. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. The Journal of experimental medicine 209: 1723–1742, S1721.

Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, Ruminski P, Weiss D, Von Schack D, and Bluestone JA. 2012. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. The Journal of experimental medicine 209: 1713–1722, S1711–1719.

Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J, Workman CJ, and Vignali DA. 2013. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501: 252–256.

Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, and Huehn J. 2007. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS biology 5: e38.

Huehn J, Polansky JK, and Hamann A. 2009. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nature reviews. Immunology 9: 83–89.

Yue X, Trifari S, Aijo T, Tsagaratou A, Pastor WA, Zepeda-Martinez JA, Lio CW, Li X, Huang Y, Vijayanand P, Lahdesmaki H, and Rao A. 2016. Control of Foxp3 stability through modulation of TET activity. The Journal of experimental medicine 213: 377–397.

Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, and Drobyski WR. 2007. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110: 3804–3813.

Wang H, and Yang YG. 2014. The complex and central role of interferon-gamma in graft-versus-host disease and graft-versus-tumor activity. Immunological reviews 258: 30–44.

Kasahara H, Kondo T, Nakatsukasa H, Chikuma S, Ito M, Ando M, Kurebayashi Y, Sekiya T, Yamada T, Okamoto S, and Yoshimura A. 2017. Generation of allo-antigen-specific induced Treg stabilized by vitamin C treatment and its application for prevention of acute graft versus host disease model. International immunology 29: 457–469.

Solomon BD, Mueller C, Chae WJ, Alabanza LM, and Bynoe MS. 2011. Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 108: 2040–2045.

Campos-Mora M, Morales RA, Gajardo T, Catalan D, and Pino-Lagos K. 2013. Neuropilin-1 in transplantation tolerance. Frontiers in immunology 4: 405.

Glinka Y, and Prud’homme GJ. 2008. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. Journal of leukocyte biology 84: 302–310.

Glinka Y, Stoilova S, Mohammed N, and Prud’homme GJ. 2011. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 32: 613–621.

Cao Y, Szabolcs A, Dutta SK, Yaqoob U, Jagavelu K, Wang L, Leof EB, Urrutia RA, Shah VH, and Mukhopadhyay D. 2010. Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. The Journal of biological chemistry 285: 31840–31848.

Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, and Ferrara JL. 1997. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90: 3204–3213.

Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, Raffelt NC, De Weerd NA, Lineburg KE, Varelias A, Markey KA, Koyama M, Clouston AD, Hertzog PJ, Macdonald KP, and Hill GR. 2011. Type I-IFNs control GVHD and GVL responses after transplantation. Blood 118: 3399–3409.

Lu Y, Sakamaki S, Kuroda H, Kusakabe T, Konuma Y, Akiyama T, Fujimi A, Takemoto N, Nishiie K, Matsunaga T, Hirayama Y, Kato J, Kon S, Kogawa K, and Niitsu Y. 2001. Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603. Blood 97: 1123–1130.

Bézie S, Meistermann D, Boucault L, Kilens S, Zoppi J, Autrusseau E, Donnart A, Nerrière-Daguin V, Bellier-Waast F, Charpentier E, Duteille F, David L, Anegon I, and Guillonneau C. 2018. Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/− Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice. Frontiers in immunology 8.